The complaint centers on claims that Insulet failed to maintain adequate oversight of its manufacturing operations, leading to safety risks for end-users. Plaintiffs allege these internal lapses rendered the company's public disclosures during the specified period materially false and misleading, violating sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
In section Releases
Insulet Corporation Faces Securities Class Action Over Manufacturing Risks
Investors who held Insulet Corporation stock between February 21, 2025, and May 26, 2026, face an August 31, 2026, deadline to join a class action lawsuit. The litigation, filed by the DJS Law Group, alleges the medical device manufacturer misled the market regarding safety controls within its production processes.
David Schwartz, a partner at DJS Law Group, is spearheading the effort to recover losses for affected shareholders. While the firm emphasizes its background in complex corporate governance and securities litigation, it notes that investors do not need to be appointed as lead plaintiffs to participate in any potential settlement or recovery. Interested parties are encouraged to contact the Eastchester-based firm ahead of the fast-approaching filing deadline.
Comments (0)
No comments yet. Be the first!